Panelists highlight that menin inhibitors represent a breakthrough in the treatment of KMT2A-rearranged AML by targeting the disease’s core epigenetic drivers, with early clinical trials like ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...

Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not yet clear.

The importance of the eight newly defined somatic mutations for AML pathogenesis is not yet known, and will require functional validation studies in tissue culture cells and mouse models to assess ...

Understanding the fundamental molecular mechanisms underlying normal hematopoiesis and AML pathogenesis can aid the development of novel and effective targeted therapies. Prof. Wang concludes by ...

The secondary-AML samples contained mutations in 11 recurrently ... more informative biomarkers and a better understanding of the pathogenesis of the myelodysplastic syndromes.

Human Y Chromosome Linked to Coronary Artery Disease Risk Adult acute myeloid leukemia (AML) genomes have an average of 13 mutations, and almost all cases have at least one nonsynonymous mutation ...

it is above all the perturbation of the RUNX1 gene -- a gene that regulates many other genes -- that seems to be responsible for AML pathogenesis. Targeting the perturbed regulator could pave the ...

An established oncogenic driver of AML pathogenesis is the FLT3 protein, which previous work has shown to be frequently mutated in AML cells. Additional work has also found that PRL2 is highly ...

Understanding the fundamental molecular mechanisms underlying normal hematopoiesis and AML pathogenesis can aid the development of novel and effective targeted therapies. Prof. Wang concludes by ...